Cell2Bio AB develops a platform for three-dimensional cell culture that enables the formation of 3D spheroids using fewer than ten cells per well, addressing the limitations of traditional 2D cell culture models. This technology enhances drug discovery and personalized medicine by providing a more accurate representation of tumor environments, allowing for effective dose optimization and monitoring of treatment responses.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional 2D cell cultures do not accurately replicate the complex anatomy and microenvironment of tumors in patients, limiting their effectiveness in drug discovery and personalized medicine. Existing 3D cell culture methods often require a high number of cells and can be difficult to use, leading to inconsistent results.
Solution
Cell2Bio AB offers a platform for three-dimensional cell culture that enables the formation of 3D spheroids using fewer than ten cells per well, addressing the limitations of traditional 2D cell culture models. This platform mimics the in-vivo tumor environment, allowing for more accurate drug testing, dose optimization, and monitoring of treatment responses. The platform is designed for ease of use and high reproducibility, providing a robust solution for generating consistent test results. By using sustainable materials and offering customizable coating options, Cell2Bio provides a versatile and environmentally conscious solution for advanced cell culture applications.
Target Audience
The primary target audience includes researchers and pharmaceutical companies involved in drug discovery, regenerative medicine, cancer research, and personalized medicine, particularly in oncology.
Features
- Enables formation of 3D spheroids with fewer than 10 cells per well
- Available on standard plate formats and customizable coatings for various surfaces
- Designed for ease of use and robust performance with high reproducibility
- Uses sustainable materials
- Supported by strong scientific evidence and granted SE Patent (2021-12-17) with PCT filed (2022-12-15)
- Validated by two scientific peer-reviewed articles